JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock

Henry Schein (NASDAQ:HSIC) had its target price raised by stock analysts at JPMorgan Chase & Co. from $78.00 to $92.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 12.93% from the company’s current price.

Several other equities research analysts also recently issued reports on HSIC. Robert W. Baird set a $100.00 price target on Henry Schein and gave the stock an “outperform” rating in a report on Monday. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wells Fargo & Company lifted their price target on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday. Barrington Research set a $79.00 price target on shares of Henry Schein and gave the company an “outperform” rating in a report on Wednesday, November 5th. Finally, Mizuho raised their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $85.58.

Henry Schein Stock Down 0.5%

Shares of NASDAQ:HSIC opened at $81.47 on Wednesday. Henry Schein has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38. The company has a market capitalization of $9.34 billion, a PE ratio of 24.91, a PEG ratio of 2.43 and a beta of 0.88. The company has a 50 day moving average price of $77.75 and a two-hundred day moving average price of $72.04.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same period last year, the firm posted $1.19 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Trading of Henry Schein

Hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after purchasing an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Henry Schein by 1.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after purchasing an additional 229 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Henry Schein in the 1st quarter valued at approximately $676,000. Asset Management One Co. Ltd. boosted its holdings in shares of Henry Schein by 9.8% in the 2nd quarter. Asset Management One Co. Ltd. now owns 8,286 shares of the company’s stock valued at $605,000 after buying an additional 739 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Henry Schein by 24.8% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,272 shares of the company’s stock valued at $458,000 after buying an additional 1,247 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.